PYC Therapeutics Limited is a biotechnology company based in Australia that focuses on the discovery and development of drug solutions in ribonucleic acid therapeutics. The company's preclinical development programs concentrate on the treatment of retinal and central nervous system diseases, such as retinitis pigmentosa type 11 and autosomal dominant optic atrophy. Since changing its name from Phylogica Limited in November 2019, PYC Therapeutics has continued to work on its drug programs, aimed at improving patient outcomes in these challenging areas.
PYC Therapeutics Limited's ticker is PYC
The company's shares trade on the LSE stock exchange
They are based in Oxford, England
There are 1-10 employees working at PYC Therapeutics Limited
It is https://pyctx.com/
PYC Therapeutics Limited is in the Healthcare sector
PYC Therapeutics Limited is in the Biotechnology industry
The following five companies are PYC Therapeutics Limited's industry peers: